Clinical Trial Update: Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of erlotinib and temozolomide in pediatric patients with recurrent or refractory solid tumors has completed. The trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma
• Ependymoma
• Germ Cell Tumor
• Medulloblastoma
• Neuroblastoma
• Primitive Neuroectodermal Tumor
• Rhabdomyosarcoma
• Soft Tissue Sarcoma

Drugs mentioned

• Tarceva (erlotinib)
• Temodar (Temozolomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Brain Tumor | Phase 1 | Status: COMPLETED